Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

XOMA Corp XOMA

XOMA Corporation is a biotechnology royalty aggregator. The Company’s royalty aggregator business is primarily focused on early to mid-stage clinical assets, primarily in Phase I and II, with significant commercial sales potential that are licensed to larger pharmaceutical partners. The Company has a portfolio of economic rights and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. Its royalty portfolio includes DAY101 (tovorafenib), JNJ-63723283 (cetrelimab), RZ358, arimoclomol, TAK-079 (mezagitamab), BAY-1213790 (osocimab), AFM13 (acimtamig), AB023 (gruticibart), AB002 (E-WE thrombin), AB054, AV-299 (ficlatuzumab), COM902, vosaroxin, aldoxorubicin, INCAGN2385, INCAGN02390, MNPR-101, PBF-680, PBF-677, PBF-999, PBF-1129, PBF-1650, G03-52-01, RZ402, DSUVIA (sufentanil sublingual tablet), IXINITY [coagulation factor IX (recombinant)], VABYSMO (faricimab-svoa), CMP-001 (vidutolimod), and CFZ533 (iscalimab).


NDAQ:XOMA - Post by User

Bullboard Posts
Post by mart33on Apr 12, 2008 12:47pm
308 Views
Post# 14964883

XOMA

XOMA This was a 2 to 10 stock and this must be where the 2 comes in. The inclusion did take this up big time but that is the way we play the Cramer. If you didn't notice (friday) he refused to endorse any tech stocks. he ran out of callers declared the lightning round over and waited for the bell. The big money is about to be made and Crame doesn't have a clue. He is about the chase the sectors and the smart money which he says you should never do. In his books he says that dicipline in #1 but in reality he goes against everything he teaches in his books. If you knew about the amount a dillution of shares for financing of this stock in the recent years you wouldn't wory about voting. A couple of years ago if you would have seen todays volume on the upside the gain would have been over 50 cents. They have to secure their debt and by the way have they gotten a new board member yet?
Bullboard Posts